Diversity and taxonomic distribution of bacterial biosynthetic gene clusters predicted to produce compounds with therapeutically relevant bioactivities.

IF 3.2 4区 生物学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Journal of Industrial Microbiology & Biotechnology Pub Date : 2023-02-17 DOI:10.1093/jimb/kuad024
Max L Beck, Siyeon Song, Isra E Shuster, Aarzu Miharia, Allison S Walker
{"title":"Diversity and taxonomic distribution of bacterial biosynthetic gene clusters predicted to produce compounds with therapeutically relevant bioactivities.","authors":"Max L Beck, Siyeon Song, Isra E Shuster, Aarzu Miharia, Allison S Walker","doi":"10.1093/jimb/kuad024","DOIUrl":null,"url":null,"abstract":"<p><p>Bacteria have long been a source of natural products with diverse bioactivities that have been developed into therapeutics to treat human disease. Historically, researchers have focused on a few taxa of bacteria, mainly Streptomyces and other actinomycetes. This strategy was initially highly successful and resulted in the golden era of antibiotic discovery. The golden era ended when the most common antibiotics from Streptomyces had been discovered. Rediscovery of known compounds has plagued natural product discovery ever since. Recently, there has been increasing interest in identifying other taxa that produce bioactive natural products. Several bioinformatics studies have identified promising taxa with high biosynthetic capacity. However, these studies do not address the question of whether any of the products produced by these taxa are likely to have activities that will make them useful as human therapeutics. We address this gap by applying a recently developed machine learning tool that predicts natural product activity from biosynthetic gene cluster (BGC) sequences to determine which taxa are likely to produce compounds that are not only novel but also bioactive. This machine learning tool is trained on a dataset of BGC-natural product activity pairs and relies on counts of different protein domains and resistance genes in the BGC to make its predictions. We find that rare and understudied actinomycetes are the most promising sources for novel active compounds. There are also several taxa outside of actinomycetes that are likely to produce novel active compounds. We also find that most strains of Streptomyces likely produce both characterized and uncharacterized bioactive natural products. The results of this study provide guidelines to increase the efficiency of future bioprospecting efforts.</p><p><strong>One-sentence summary: </strong>This paper combines several bioinformatics workflows to identify which genera of bacteria are most likely to produce novel natural products with useful bioactivities such as antibacterial, antitumor, or antifungal activity.</p>","PeriodicalId":16092,"journal":{"name":"Journal of Industrial Microbiology & Biotechnology","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2023-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10548851/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Industrial Microbiology & Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1093/jimb/kuad024","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Bacteria have long been a source of natural products with diverse bioactivities that have been developed into therapeutics to treat human disease. Historically, researchers have focused on a few taxa of bacteria, mainly Streptomyces and other actinomycetes. This strategy was initially highly successful and resulted in the golden era of antibiotic discovery. The golden era ended when the most common antibiotics from Streptomyces had been discovered. Rediscovery of known compounds has plagued natural product discovery ever since. Recently, there has been increasing interest in identifying other taxa that produce bioactive natural products. Several bioinformatics studies have identified promising taxa with high biosynthetic capacity. However, these studies do not address the question of whether any of the products produced by these taxa are likely to have activities that will make them useful as human therapeutics. We address this gap by applying a recently developed machine learning tool that predicts natural product activity from biosynthetic gene cluster (BGC) sequences to determine which taxa are likely to produce compounds that are not only novel but also bioactive. This machine learning tool is trained on a dataset of BGC-natural product activity pairs and relies on counts of different protein domains and resistance genes in the BGC to make its predictions. We find that rare and understudied actinomycetes are the most promising sources for novel active compounds. There are also several taxa outside of actinomycetes that are likely to produce novel active compounds. We also find that most strains of Streptomyces likely produce both characterized and uncharacterized bioactive natural products. The results of this study provide guidelines to increase the efficiency of future bioprospecting efforts.

One-sentence summary: This paper combines several bioinformatics workflows to identify which genera of bacteria are most likely to produce novel natural products with useful bioactivities such as antibacterial, antitumor, or antifungal activity.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
细菌生物合成基因簇的多样性和分类分布预测产生具有治疗相关生物活性的化合物。
长期以来,细菌一直是具有多种生物活性的天然产物的来源,这些产物已被开发成治疗人类疾病的疗法。历史上,研究人员一直关注少数细菌分类群,主要是链霉菌和其他放线菌。这一策略最初非常成功,并开创了抗生素发现的黄金时代。当链霉菌中最常见的抗生素被发现时,黄金时代结束了。从那以后,已知化合物的重新发现一直困扰着天然产物的发现。最近,人们对鉴定产生生物活性天然产物的其他分类群越来越感兴趣。一些生物信息学研究已经确定了具有高生物合成能力的有前景的分类群。然而,这些研究并没有解决这些分类群产生的任何产品是否可能具有使其作为人类治疗药物有用的活性的问题。我们通过应用最近开发的机器学习工具来解决这一差距,该工具预测生物合成基因簇(BGC)序列的天然产物活性,以确定哪些分类群可能产生不仅新颖而且具有生物活性的化合物。该机器学习工具在BGC天然产物活性对的数据集上进行训练,并依赖于BGC中不同蛋白质结构域和抗性基因的计数来进行预测。我们发现,稀有和研究不足的放线菌是最有前途的新活性化合物来源。放线菌之外还有几个分类群可能产生新的活性化合物。我们还发现,大多数链霉菌菌株可能产生具有特征和未特征的生物活性天然产物。这项研究的结果为提高未来生物勘探工作的效率提供了指导。一句话总结:本文结合了几个生物信息学工作流程,以确定哪些属的细菌最有可能产生具有有用生物活性的新型天然产物,如抗菌、抗肿瘤或抗真菌活性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Industrial Microbiology & Biotechnology
Journal of Industrial Microbiology & Biotechnology 工程技术-生物工程与应用微生物
CiteScore
7.70
自引率
0.00%
发文量
25
审稿时长
3 months
期刊介绍: The Journal of Industrial Microbiology and Biotechnology is an international journal which publishes papers describing original research, short communications, and critical reviews in the fields of biotechnology, fermentation and cell culture, biocatalysis, environmental microbiology, natural products discovery and biosynthesis, marine natural products, metabolic engineering, genomics, bioinformatics, food microbiology, and other areas of applied microbiology
期刊最新文献
Use of qPCR to Monitor 2,4-Dinitroanisole Degrading Bacteria in Water and Soil Slurry Cultures. Enhancing the erythritol production of Yarrowia lipolytica by high-throughput screening based on highly sensitive artificial sensor and anchor protein cwp2. Characterization of the exopolysaccharides produced by the industrial yeast Komagataella phaffii. A synthetic co-culture for bioproduction of ammonia from methane and air. Valorizing Waste Streams to Enhance Sustainability and Economics in Microbial Oil Production.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1